Cargando…

Analytical validation of a novel multi-analyte plasma test for lung nodule characterization

BACKGROUND: In the National Lung Screening Trial, 96.4% of nodules had benign etiology. To avoid unnecessary actions and exposure to harm, individuals with benign disease must be identified. We describe herein the analytical validation of a multi-analyte immunoassay for characterizing the risk that...

Descripción completa

Detalles Bibliográficos
Autores principales: Trivedi, Neil N, Brown, James K, Rubenstein, Tess, Rostykus, Abigail D, Fish, Amanda L, Yu, Heng, Carbonell, Luis, Juang, Alice, Kamer, Sandy, Patel, Bhavin, Sidhu, Manpreet, Vuong, Doris, Wang, Shan, Beggs, Mike, Wu, Alan HB, Arjomandi, Mehrdad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486005/
https://www.ncbi.nlm.nih.gov/pubmed/32923944
http://dx.doi.org/10.15761/brr.1000123
_version_ 1783581259597873152
author Trivedi, Neil N
Brown, James K
Rubenstein, Tess
Rostykus, Abigail D
Fish, Amanda L
Yu, Heng
Carbonell, Luis
Juang, Alice
Kamer, Sandy
Patel, Bhavin
Sidhu, Manpreet
Vuong, Doris
Wang, Shan
Beggs, Mike
Wu, Alan HB
Arjomandi, Mehrdad
author_facet Trivedi, Neil N
Brown, James K
Rubenstein, Tess
Rostykus, Abigail D
Fish, Amanda L
Yu, Heng
Carbonell, Luis
Juang, Alice
Kamer, Sandy
Patel, Bhavin
Sidhu, Manpreet
Vuong, Doris
Wang, Shan
Beggs, Mike
Wu, Alan HB
Arjomandi, Mehrdad
author_sort Trivedi, Neil N
collection PubMed
description BACKGROUND: In the National Lung Screening Trial, 96.4% of nodules had benign etiology. To avoid unnecessary actions and exposure to harm, individuals with benign disease must be identified. We describe herein the analytical validation of a multi-analyte immunoassay for characterizing the risk that a lung nodule found on CT is malignant. Those at lower risk may be considered for serial surveillance to avoid unnecessary and potentially harmful procedures. While those nodules characterized at higher risk may be appropriate for more aggressive actions. OBJECTIVE: To validate the analytical performance of multiplexed plasma protein assays used in a novel test for lung nodule characterization. METHODS: A multiplexed immunoassay panel for the measurement of plasma proteins in current smokers who present with a lung nodule on CT scan was evaluated in a clinical testing laboratory. Assay analytical sensitivity, reproducibility, precision, and recovery of Epidermal Growth Factor Receptor (EGFR), Prosurfactant protein B (ProSB), and Tissue Inhibitor of Metalloproteinases 1 (TIMP1) from human EDTA plasma samples were evaluated across multiple runs, lots, and technicians. Interfering substances and sample pre-analytical storage conditions were evaluated for their effect on analyte recovery. The lung nodule risk score reproducibility was assessed across multiple lots. RESULTS: The assay sensitivities were 0.10 ng/mL EGFR, 0.02 ng/mL ProSB, and 0.29 ng/mL TIMP1 with over three orders of magnitude in the assay dynamic ranges. The assays and analytes are robust to pre-analytical sample handling and the plasma can be stored for up to 4 days at 4°C either when freshy collected or thawed after long-term storage at −80°C. Total imprecision after 20 days of testing remained under 9% for all three assays. Risk score variability remained within a ± 10% risk score range. CONCLUSIONS: The three protein assays comprising the multi-analyte plasma test for lung nodule characterization performed quite acceptably in a clinical laboratory.
format Online
Article
Text
id pubmed-7486005
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-74860052020-09-11 Analytical validation of a novel multi-analyte plasma test for lung nodule characterization Trivedi, Neil N Brown, James K Rubenstein, Tess Rostykus, Abigail D Fish, Amanda L Yu, Heng Carbonell, Luis Juang, Alice Kamer, Sandy Patel, Bhavin Sidhu, Manpreet Vuong, Doris Wang, Shan Beggs, Mike Wu, Alan HB Arjomandi, Mehrdad Biomed Res Rev Article BACKGROUND: In the National Lung Screening Trial, 96.4% of nodules had benign etiology. To avoid unnecessary actions and exposure to harm, individuals with benign disease must be identified. We describe herein the analytical validation of a multi-analyte immunoassay for characterizing the risk that a lung nodule found on CT is malignant. Those at lower risk may be considered for serial surveillance to avoid unnecessary and potentially harmful procedures. While those nodules characterized at higher risk may be appropriate for more aggressive actions. OBJECTIVE: To validate the analytical performance of multiplexed plasma protein assays used in a novel test for lung nodule characterization. METHODS: A multiplexed immunoassay panel for the measurement of plasma proteins in current smokers who present with a lung nodule on CT scan was evaluated in a clinical testing laboratory. Assay analytical sensitivity, reproducibility, precision, and recovery of Epidermal Growth Factor Receptor (EGFR), Prosurfactant protein B (ProSB), and Tissue Inhibitor of Metalloproteinases 1 (TIMP1) from human EDTA plasma samples were evaluated across multiple runs, lots, and technicians. Interfering substances and sample pre-analytical storage conditions were evaluated for their effect on analyte recovery. The lung nodule risk score reproducibility was assessed across multiple lots. RESULTS: The assay sensitivities were 0.10 ng/mL EGFR, 0.02 ng/mL ProSB, and 0.29 ng/mL TIMP1 with over three orders of magnitude in the assay dynamic ranges. The assays and analytes are robust to pre-analytical sample handling and the plasma can be stored for up to 4 days at 4°C either when freshy collected or thawed after long-term storage at −80°C. Total imprecision after 20 days of testing remained under 9% for all three assays. Risk score variability remained within a ± 10% risk score range. CONCLUSIONS: The three protein assays comprising the multi-analyte plasma test for lung nodule characterization performed quite acceptably in a clinical laboratory. 2018-11-23 2018-12 /pmc/articles/PMC7486005/ /pubmed/32923944 http://dx.doi.org/10.15761/brr.1000123 Text en This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Trivedi, Neil N
Brown, James K
Rubenstein, Tess
Rostykus, Abigail D
Fish, Amanda L
Yu, Heng
Carbonell, Luis
Juang, Alice
Kamer, Sandy
Patel, Bhavin
Sidhu, Manpreet
Vuong, Doris
Wang, Shan
Beggs, Mike
Wu, Alan HB
Arjomandi, Mehrdad
Analytical validation of a novel multi-analyte plasma test for lung nodule characterization
title Analytical validation of a novel multi-analyte plasma test for lung nodule characterization
title_full Analytical validation of a novel multi-analyte plasma test for lung nodule characterization
title_fullStr Analytical validation of a novel multi-analyte plasma test for lung nodule characterization
title_full_unstemmed Analytical validation of a novel multi-analyte plasma test for lung nodule characterization
title_short Analytical validation of a novel multi-analyte plasma test for lung nodule characterization
title_sort analytical validation of a novel multi-analyte plasma test for lung nodule characterization
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486005/
https://www.ncbi.nlm.nih.gov/pubmed/32923944
http://dx.doi.org/10.15761/brr.1000123
work_keys_str_mv AT trivedineiln analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization
AT brownjamesk analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization
AT rubensteintess analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization
AT rostykusabigaild analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization
AT fishamandal analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization
AT yuheng analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization
AT carbonellluis analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization
AT juangalice analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization
AT kamersandy analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization
AT patelbhavin analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization
AT sidhumanpreet analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization
AT vuongdoris analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization
AT wangshan analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization
AT beggsmike analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization
AT wualanhb analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization
AT arjomandimehrdad analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization